The 2014 multiple myeloma market garnered impressive sales despite its relatively low incidence compared with other oncology markets with similar revenues. Significant achievements in clinical practice over the last decade and the launches of efficacious, premium-priced agents are set to drive market expansion through 2024. Despite these advances, untapped market potential remains for agents that can improve the prognosis and overall survival compared with currently available agents.
Questions Answered in This Report:
- First-in-class HDAC inhibitor panobinostat (Novartis’s Farydak) received approval in the United States, Europe, and Japan in 2015. What is this therapy’s sales potential in the multiple myeloma market during out forecast period? What are thought leaders’ opinion of this agent and of HDAC inhibitors in general?
- Lenalidomide (Celgene’s Revlimid) received a label expansion in the United States and Europe in 2015 for use among newly diagnosed transplant-eligible and transplant-ineligible multiple myeloma patients. What are the patient share and sales implications for lenalidomide’s label extension for newly diagnosed multiple myeloma in these regions?
- We forecast robust annual growth in the multiple myeloma market through 2024. Which lines of treatment will experience the most growth? What market events will impact sales of Janssen/Takeda Pharmaceutical’s Velcade, Celgene’s Pomalyst/Imnovid and Revlimid, and Amgen/Onyx Pharmaceuticals/Ono Pharmaceutical’s Kyprolis? When do we anticipate major inflection points in market growth and constraint?
- Intense clinical development is under way in multiple myeloma to emulate the commercial success of the four major agents currently used to treat the disease. Will daratumumab, elotuzumab, and ixazomib replace Velcade, Revlimid, Pomalyst/Imnovid, and Kyprolis in the multiple myeloma treatment algorithm? What advantages do these emerging agents exhibit over current therapies? Are proteasome inhibitors and cell-surface targeted agents the only promising classes of agents in development?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 22 country-specific interviews with leading hematological oncologists and survey data from 30 physicians in each of the major markets who treat at least 78 multiple myeloma patients per year.
Epidemiology: Diagnosed incident cases of multiple myeloma, diagnosed incident cases of monoclonal gammopathy of undetermined significance (MGUS).
Population segments in market forecast: Drug-treatable patients with symptomatic myeloma including first- (transplant-eligible and transplant-ineligible), second-, third-, and fourth-line segments.
Emerging therapies: Phase II: 11 drugs; Phase III: 4 drugs; registered: 3 drugs. Coverage of 7 select Phase I products.
Sarah Anderson, M.Sc.